<DOC>
	<DOCNO>NCT00434473</DOCNO>
	<brief_summary>The study conduct 15-20 US center randomize , placebo-controlled , double-blind fashion . Enrollees hospitalize sickle cell disease ( SCD ) patient at-risk acute chest syndrome ( ACS ) base presence vaso-occlusive crisis ( VOC ) , fever ( T ≥38.0°C ) serum sPLA2 concentration ≥50 ng/mL .</brief_summary>
	<brief_title>IMPACTS Trial : Investigation Modulation Phospholipase Acute Chest Syndrome</brief_title>
	<detailed_description>This double-blind randomized , parallel group , placebo-controlled dose escalation study ( 2 cohort ) patient sickle cell disease ( SCD ) vaso-occlusive crisis ( VOC ) at-risk development acute chest syndrome ( ACS ) base combination VOC , fever ( T ≥38.0ºC ) , serum sPLA2 concentration ≥50 ng/mL . The first group patient randomize 2:1 receive low dose A-001 placebo 48-hour continuous infusion . Pharmacokinetic clinical data group undergo review Independent Data Monitoring Committee ( IDMC ) . If significant toxicity associate A-001 , additional group patient enrol randomized 2:1 high dose A-001 versus placebo 48-hour continuous infusion .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<mesh_term>Acute Chest Syndrome</mesh_term>
	<criteria>Patients eligible inclusion meet follow criterion : Sickle cell variant ( Hb SS , Hb SC , sickle β°—thalassemia , sickle β+—thalassemia ) Pain consistent vasoocclusive crisis Elevated serum sPLA2 level ( measure onsite ) Fever Age ≥5 year ( adult ) Patients must NOT meet follow exclusion criterion : New lung infiltrate chest radiography Pregnancy breastfeed Significant renal dysfunction Significant hepatic dysfunction Acute neurologic dysfunction Any medical condition transfusion may need imminently , and/or hemoglobin &lt; 5 g/dL Red blood cell transfusion within 30 day entry study</criteria>
	<gender>All</gender>
	<minimum_age>5 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>